menu
    • menu
    [{"orgOrder":0,"company":"Vensica Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Urology","graph2":"Approved FDF","graph3":"Vensica Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vensica Medical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Vensica Medical \/ Undisclosed"},{"orgOrder":0,"company":"Vensica Medical","sponsor":"Israel Biotech Fund","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Protein","year":"2024","type":"Funding","leadProduct":"Incobotulinumtoxin A","moa":"SNAP25","graph1":"Urology","graph2":"Phase I","graph3":"Vensica Medical","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Vensica Medical \/ Israel Biotech Fund","highestDevelopmentStatusID":"6","companyTruncated":"Vensica Medical \/ Israel Biotech Fund"}]

    Find Clinical Drug Pipeline Developments & Deals by Vensica Medical

    Menu

    Vensica Medical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vensica Medical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Vensica Medical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Incobotulinumtoxin A

                            Therapeutic Area : Urology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Health Canada Approves XEOMIN® for Post-stroke Spasticity Treatment in Adults

                            Details : Xeomin (Incobotulinumtoxin A) is a SNAP25 inhibitor drug candidate, which is approved and indicated for the treatment of post-stroke lower limb spasticity involving the ankle and foot in adults.

                            Product Name : Xeomin

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 17, 2024

                            Lead Product(s) : Incobotulinumtoxin A

                            Therapeutic Area : Urology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vensica Medical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Vensica Medical

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Incobotulinumtoxin A

                            Therapeutic Area : Urology

                            Study Phase : Phase I

                            Sponsor : Israel Biotech Fund

                            Deal Size : $11.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Vensica Medical Secures $11M for Overactive Bladder Phase 2 Trials

                            Details : The fund will support the company's mid-stage clinical trials for its revolutionary treatment of overactive bladder using Xeomin (Incobotulinumtoxin A), delivered through a needle-free device.

                            Product Name : Xeomin

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            October 28, 2024

                            Lead Product(s) : Incobotulinumtoxin A

                            Therapeutic Area : Urology

                            Highest Development Status : Phase I

                            Sponsor : Israel Biotech Fund

                            Deal Size : $11.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth